Erectile dysfunction is more often a symptom of underlying physiology than a standalone problem. This protocol walks the evidence-based stepwise approach: cardiometabolic and hormonal workup, lifestyle optimization, first-line PDE5 inhibitors, second-line approaches (PT-141, vacuum devices, intracavernosal), and when to escalate. Cross-references the underlying compound monographs.

Evidence and pricing are current as of May 2026; new trials may change the picture.

Why This Protocol Exists

Erectile dysfunction (ED) affects approximately 40% of men by age 40 and 70% by age 70. The common framing — 'man takes a blue pill, problem solved' — substantially understates both the underlying physiology and the available tools. ED is frequently the earliest symptom of cardiovascular disease (endothelial dysfunction in the penile vasculature precedes coronary disease by 3-5 years on average), an early signal of hypogonadism, a manifestation of mental health and relationship factors, or some combination of all of these. A stepwise evaluation and management approach produces substantially better outcomes than ad-hoc PDE5 prescribing.

This protocol synthesizes the evidence-based approach: workup first, lifestyle and underlying-condition optimization, first-line PDE5 inhibitors, second-line pharmacological options including PT-141, mechanical and injection approaches, and when to escalate to urological or vascular specialist evaluation. Each section cross-references the underlying compound monographs for compound-level detail.

Important framing: ED is a symptom. The first move is identifying the underlying drivers, not just prescribing a PDE5. Patients with newly recognized ED warrant cardiovascular and metabolic workup regardless of any treatment plan.

Step 1 — Workup

Baseline evaluation in any new ED presentation:

Cardiovascular workup. Blood pressure, lipid panel, fasting glucose or HbA1c. Family history. Smoking status. Sedentary status. ED often precedes recognized cardiovascular disease by years; new ED is a flag to formalize cardiovascular risk assessment.

Hormonal workup. Morning total testosterone (ideally 8-10 AM, fasting). If low or borderline, repeat plus free testosterone, SHBG, LH, FSH, prolactin. TSH. Hypogonadism is a recognized contributor to ED and treatable.

Diabetes/metabolic. HbA1c. Diabetes is a major contributor to ED through both microvascular and neuropathic mechanisms.

Medication review. SSRIs, beta-blockers, thiazide diuretics, anti-androgens, finasteride/dutasteride, alcohol and recreational drug use. Many medications contribute; some can be substituted.

Mental health and relationship. Depression, anxiety, performance anxiety, relationship dynamics, history of sexual trauma. These are major drivers and often the dominant factor in younger men.

Sleep. Sleep apnea diagnosis or screening. Sleep apnea is associated with both ED and hypogonadism; CPAP treatment can improve both.

Pelvic floor evaluation. Pelvic floor dysfunction is an under-recognized contributor. Cross-reference: pelvic floor PT monograph.

Step 2 — Lifestyle Foundation

These are not optional adjuncts — they substantially modify outcomes regardless of pharmacological strategy:

  • Weight loss. Even modest (5-10%) weight loss in overweight/obese men can substantially improve erectile function and testosterone levels.
  • Exercise. Aerobic exercise improves endothelial function. Resistance training supports testosterone. Both substantially benefit ED.
  • Smoking cessation. Among the most impactful single interventions for ED.
  • Alcohol reduction. Chronic heavy use is a major contributor.
  • Sleep optimization. Both sleep quantity and quality affect testosterone and erectile function.
  • Mediterranean dietary pattern. Substantial evidence for improving ED via cardiovascular and metabolic pathways.

Step 3 — First-Line Pharmacology: PDE5 Inhibitors

PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are first-line pharmacological treatment for ED with substantial evidence for efficacy and safety. They produce ~70-85% response rates in appropriate patients.

Sildenafil (Viagra). 25-100 mg as needed, 30-60 min before activity. Duration ~4-6 hours. Generic since 2017; substantially lower cost. Food (especially fatty meal) slows onset.

Tadalafil (Cialis). Two approaches: as-needed 10-20 mg (duration ~36 hours), or daily low-dose 2.5-5 mg (continuous effect). Daily dosing also FDA-approved for BPH symptoms, providing dual benefit. Generic since 2018.

Vardenafil (Levitra). 10-20 mg as needed. Similar duration to sildenafil. Some patients prefer the side effect profile.

Avanafil (Stendra). 100-200 mg as needed. Faster onset (~15-30 min). Newer agent, branded.

Practical considerations:

  • Effectiveness substantially improved with adequate sexual stimulation — PDE5 alone does not produce erection without arousal
  • Daily tadalafil often preferred for spontaneity and for patients with mild ED + BPH
  • Try multiple agents before declaring 'PDE5 failure' — individual variation is substantial
  • Adequate dosing trial: at least 6-8 attempts with proper timing before declaring inadequate
  • Cross-reference: PDE5 inhibitor comparison monograph

Contraindications. Concurrent nitrate use (absolute). Severe cardiovascular disease (relative). Concurrent alpha-blocker use requires dose adjustment. Severe hepatic or renal impairment may require dose reduction.

Step 4 — Optimize Underlying Conditions

If workup identified contributing conditions, optimize them in parallel with PDE5 trial:

Hypogonadism. If testosterone documented low (typically <300 ng/dL on two morning measurements) with symptoms, testosterone therapy improves ED in many patients, especially in combination with PDE5. PDE5 alone may underperform if testosterone substantially low. Cross-reference: TRT monograph.

Diabetes. Glycemic control improves ED. Many patients see ED improvement with HbA1c reduction.

Cardiovascular disease. Risk factor modification (statin, BP control, smoking cessation) improves ED through endothelial mechanisms.

Mental health. Depression treatment, anxiety treatment, couples therapy, sex therapy as indicated. SSRI-induced ED may improve with agent switching.

Sleep apnea. CPAP treatment improves both testosterone and ED.

Step 5 — Second-Line Pharmacological Options

When PDE5 inhibitors at adequate doses with adequate trial duration are insufficient or contraindicated:

PT-141 (bremelanotide). Melanocortin receptor agonist. Subcutaneous injection 30-60 min before activity. Centrally-acting mechanism (different from PDE5 vascular mechanism); can work when PDE5 fails. Common side effects: nausea, flushing, headache. Cross-reference: PT-141 monograph.

Combination PDE5 + PT-141. Some patients benefit from combination when monotherapy with either insufficient.

Trimix or bimix intracavernosal injection. Combination of papaverine, phentolamine, and/or alprostadil. Substantial efficacy (~80-90% response). Self-injection requires patient education. Reserved for PDE5 failure.

Intraurethral alprostadil (MUSE). Suppository form. Less effective than injection but no needle. Alternative for some patients.

Topical alprostadil (Vitaros). Available in some markets. Less effective than systemic options.

Step 6 — Mechanical Options

Vacuum erection devices. Mechanical alternative or adjunct. Effective for most patients regardless of underlying mechanism. Constriction ring required to maintain erection. Some patients find acceptable; others not. Useful in PDE5-contraindicated patients (nitrate users).

Pelvic floor PT. For patients with pelvic floor component (Dorey 2005 demonstrated benefit comparable to vacuum device or surgery in selected populations). Cross-reference: pelvic floor PT monograph.

Step 7 — When to Escalate to Specialist

Urology or sexual medicine specialist referral:

  • PDE5 failure with appropriate trial
  • Sudden-onset ED without clear cause
  • ED with significant pain or anatomic abnormalities
  • Peyronie's disease suspected
  • Patient interest in penile implant or vascular surgery
  • Complex hormonal cases requiring endocrinology

Surgical options. Penile implant (inflatable or malleable) — highly effective but invasive; reserved for refractory cases. Vascular surgery — limited role in modern practice.

Newer and Emerging Therapies

Low-intensity shockwave therapy. Some evidence in mild-to-moderate vasculogenic ED. Multiple sessions over weeks. Variable evidence; promising but not yet established standard of care.

Stem cell therapy. Experimental. Limited high-quality evidence. Substantial cost. Currently not standard.

Platelet-rich plasma injection. Marketed but evidence limited.

The Honest Stepwise Algorithm

Practical clinician approach:

  • 1. Workup as above. Don't skip.
  • 2. Lifestyle interventions in parallel. Don't skip these either.
  • 3. PDE5 trial. Adequate dose, adequate timing, adequate number of attempts. Try multiple agents before declaring failure.
  • 4. Optimize underlying conditions: testosterone, diabetes, mental health, sleep apnea.
  • 5. Second-line: PT-141, combination PDE5+PT-141, vacuum device.
  • 6. Third-line: intracavernosal injection.
  • 7. Specialist referral for refractory cases or anatomic issues.

The vast majority of ED responds to steps 1-4. Many patients are inadequately worked up and inadequately optimized before being labeled 'PDE5 failure.' The protocol matters.

Bottom Line

Erectile dysfunction is typically a symptom of underlying physiology, not an isolated problem. The stepwise approach — workup, lifestyle, PDE5, underlying condition optimization, second-line pharmacology, mechanical options, specialist referral — produces substantially better outcomes than ad-hoc PDE5 prescribing. New ED warrants cardiovascular and metabolic workup regardless of treatment plan. Most ED responds to PDE5 + lifestyle + underlying condition optimization. The remainder benefits from second-line approaches before reaching surgical territory.

Educational Disclaimer

This monograph is published by Vanguard Optimization as physician-led, evidence-based education. It is not medical advice. We do not prescribe, diagnose, or establish doctor–patient relationships. Decisions about supplementation or medication should be made with the clinician who knows you and your specific clinical situation. The signal-grading and editorial choices in this document represent our best read of the published literature as of May 2026; new data may change them.

Cross-Referenced Monographs

PDE5 Inhibitor Comparison — sildenafil, tadalafil, vardenafil, avanafil

PT-141 (Bremelanotide) — melanocortin receptor agonist

Testosterone Replacement Therapy — TRT monograph

Pelvic Floor Physical Therapy for Men

SSRIs — Long-Term Use and PSSD